NEW YORK (GenomeWeb) – Waters today announced that it will establish a joint open laboratory with the Chinese Pharmacopoeia Commission.
The lab, which will be located in the Beijing Zhendong Guangming Drug Research Institute, is slated to open by the end of the year. Activities there will be directed at research into pharmacopoeia standards, developing testing methods, validating the methods, and providing training in pharmacopoeia detection methods. The lab, the partners said, is anticipated to become a national technical support center in Chinese pharmaceutical standards.
The lab will be more than 1,300 square feet and will be outfitted with a range of Waters' chromatography instruments and mass spectrometers. It also will offer a natural products application solution with UNIFI, the firm's biopharmaceutical platform that integrates UPLC/MS characterization technology with software for bioseparations, intact protein mass analysis, peptide mapping, and glycan analysis.
Financial and other terms of the agreement were not disclosed.